Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
25.61
-0.65 (-2.48%)
At close: Aug 28, 2026, 4:00 PM EDT
25.68
+0.07 (0.27%)
After-hours: Aug 28, 2026, 7:30 PM EDT
Ultragenyx Pharmaceutical Revenue
Ultragenyx Pharmaceutical had revenue of $214.00M in the quarter ending June 30, 2026, with 28.14% growth. This brings the company's revenue in the last twelve months to $717.21M, up 17.55% year-over-year. In the year 2025, Ultragenyx Pharmaceutical had annual revenue of $673.00M with 20.18% growth.
Revenue (ttm)
$717.21M
Revenue Growth
+17.55%
P/S Ratio
3.51
Revenue / Employee
$522,976
Employees
1,371
Market Cap
2.52B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 673.00M | 113.00M | 20.18% |
| Dec 31, 2024 | 560.00M | 126.00M | 29.03% |
| Dec 31, 2023 | 434.00M | 70.67M | 19.45% |
| Dec 31, 2022 | 363.33M | 11.92M | 3.39% |
| Dec 31, 2021 | 351.41M | 80.38M | 29.66% |
| Dec 31, 2020 | 271.03M | 167.32M | 161.32% |
| Dec 31, 2019 | 103.71M | 52.22M | 101.41% |
| Dec 31, 2018 | 51.50M | 48.88M | 1,871.48% |
| Dec 31, 2017 | 2.61M | 2.48M | 1,863.91% |
| Dec 31, 2016 | 133.00K | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Nuvation Bio | 169.90M |
| Precigen | 85.72M |
| Viridian Therapeutics | 71.13M |
| Nektar Therapeutics | 54.59M |
| AtaiBeckley | 4.47M |
RARE News
- 1 day ago - Ultragenyx price target raised to $50 from $46 at Wells Fargo - TheFly
- 4 days ago - Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 days ago - Ultragenyx price target raised to $80 from $75 at JPMorgan - TheFly
- 8 days ago - Ultragenyx price target raised to $74 from $67 at Morgan Stanley - TheFly
- 8 days ago - Ultragenyx price target raised to $48 from $46 at BofA - TheFly
- 9 days ago - Ultragenyx Pharmaceutical (RARE) Stock Jumps 9% on Accelerated FDA Approval - TipRanks
- 9 days ago - Ultragenyx price target raised to $103 from $96 at Cantor Fitzgerald - TheFly
- 9 days ago - Ultragenyx price target raised to $83 from $81 at Canaccord - TheFly